- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03885349
Motivational Strategies in Batterer Intervention Programs for Offenders With Alcohol/Drug Abuse Problems (IMP-ADAPs) (IMP-ADAPs)
December 5, 2023 updated by: University of Valencia
Motivational Strategies in Batterer Intervention Programs for Intimate Partner Violence Offenders With Alcohol/Drug Abuse Problems: An Experimental Study
Alcohol and/or drug abuse problems (ADAPs) have been consistently identified in the scientific literature as a risk factor of intimate partner violence against women (IPVAW).
Around 50% of IPVAW offenders referred to batterer intervention programs (BIPs) have ADAPs.
ADAPs are also one of the main predictors of BIPs dropout.
In Spain, the majority of BIPs do not fit the intervention to specific needs or characteristics of IPVAW offenders, such as those with ADAPs.
The aim of this research is to assess the effectiveness of a new motivational strategy adapted to IPVAW offenders with ADAPs, aiming to increase treatment adherence and to improve BIPs outcomes.
The motivational strategy will include an individualized motivational plan (IMP) developed for each participant with ADAPs (IMP-ADAPs).
In these IMPs one of the main aims will be to reduce alcohol and/or drug consumption.
The current study will use a randomized control trial.
Participants with ADAPs will be allocated to one of two treatment conditions: experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan focused in ADAPs (SBIP+ ADAPs-IMP), and control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP).
Primary/final outcomes will be recidivism and ADAPs reduction.
Secondary/proximal outcomes will include treatment adherence related variables, violence related attitudes and attributions, self-control and psychological adjustment.
Outcome variables will be assessed at baseline, at the end of the intervention, and at six months after the intervention will be finished.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elena Terreros, PhD
- Phone Number: +3463030607983918
- Email: elenaterreros@gmail.com
Study Locations
-
-
-
Valencia, Spain, 46010
- Recruiting
- Faculty of Psychology
-
Contact:
- Elena Terreros, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males convicted of IPV against their partner or ex-partner
- Alcohol and/or drugs abuse problems
Exclusion Criteria:
- No current severe psychological disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SBIP+ ADAPs-IMP
Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
|
Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems.
The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality.
The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills).
The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
|
Active Comparator: SBIP+IMP
Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
|
Standard batterer intervention program plus Individualized Motivational Plans.
The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality.
The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills).
The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in alcohol abuse problems
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Alcohol Use Disorders Identification Test.
Saunders, Aasland, Babor, De la Fuente, & Grant, 1993.
Total scale range: 0-20 (Higher values indicate worse outcome).
|
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Change in cannabis abuse problems
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Severity Dependence Scale.
Gossop et al., 1995.
Total scale range: 0-15 (Higher values indicate worse outcome).
|
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Change in cocaine abuse problems
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Severity Dependence Scale.
Gossop et al., 1995.
Total scale range: 0-15 (Higher values indicate worse outcome).
|
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Change in self-reported physical intimate partner violence against women
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Self-reported physical violence sub-scale from the Conflict Tacticts Scale.
Straus, Hamby, Boney-McCoy y Sugarman, 1996.
Total scale range: 0-72 (Higher values indicate worse outcome).
|
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Change in self-reported psychological intimate partner violence against women
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Self-reported psychological violence sub-scale from the Conflict Tacticts Scale.
Straus, Hamby, Boney-McCoy y Sugarman, 1996.
Total scale range: 0-72 (Higher values indicate worse outcome).
|
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Change in risk of recidivism
Time Frame: At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
The Spousal Assault Risk Assessment.
SARA; Kropp y Hart, 2000.
Total scale range: 0-40 (Higher values indicate worse outcome)
|
At baseline, at 12 months (end of intervention), and at 18 months (follow-up)
|
Police-reported recidivism
Time Frame: At 18 months (follow-up)
|
Ministry of Home Affairs' monitoring system for IPV.
This system includes information on further incidents of violence by individuals convicted of IPV and reported by any of the institutions involved in victim protection services.
Recidivism will be considered to have occurred when this information appear in the system in the 6 months after completing the intervention.
|
At 18 months (follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Therapeutic alliance
Time Frame: 4 weeks after the first session of the intervention
|
Working Alliance Inventory Shortened Observer-rated version (WAI-O-S; Tichenor & Hill, 1989).
Total scale range: 0-74 (Higher values indicate better outcome)
|
4 weeks after the first session of the intervention
|
Change in motivation
Time Frame: At baseline, at 6 months, and at 12 months (end of intervention)
|
Based on the transtheoretical model of change (Prochaska and DiClemente, 1982; Prochaska et al., 1992), therapists will rate participants' stage of change (pre-contemplation, contemplation, preparation, action, and maintenance).
Total range: 1-5 (Higher values indicate better outcome).
|
At baseline, at 6 months, and at 12 months (end of intervention)
|
Change in impulsivity
Time Frame: At baseline and at 12 months (end of intervention)
|
Plutchik Impulsivity Scale; Plutchnik y Van Pragg, 1989.
Total scale range: 11-44 (Higher values indicate worse outcome)
|
At baseline and at 12 months (end of intervention)
|
Change in depressive symptomatology
Time Frame: At baseline and at 12 months (end of intervention)
|
Spanish reduced version of the Center for Epidemiology Studies-Depression Scale; Herrero y Gracia, 2007.
Total scale range: 7-28 (Higher values indicate worse outcome)
|
At baseline and at 12 months (end of intervention)
|
Change in self-esteem
Time Frame: At baseline and at 12 months (end of intervention)
|
Rosenberg Self-Esteem Scale.
Rosenberg, 1965.
Total scale range: 10-40 (Higher values indicate better outcome)
|
At baseline and at 12 months (end of intervention)
|
Attributions of Responsibility
Time Frame: At baseline and at 12 months (end of intervention)
|
Intimate Partner Violence Responsibility Atribution Scale.
Lila, Oliver, Catalá-Miñana, Galiana y Gracia, 2014.
Three sub-scales: responsibility attribution to the legal system (sub-scale range: 4-20), responsibility attribution to the victim (sub-scale range: 4-20), and responsibility attribution to the offender personal context (sub-scale range: 4-20).
Higher values indicate worse outcome.
|
At baseline and at 12 months (end of intervention)
|
Change in perceived severity of intimate partner violence against women
Time Frame: At baseline and at 12 months (end of intervention)
|
Severity Perception of Intimate Partner Violence Against Women Scale.
Gracia, García y Lila (2011).
Total scale range: 8-80 (Higher values indicate better outcome)
|
At baseline and at 12 months (end of intervention)
|
Change in acceptability of intimate partner violence against women
Time Frame: At baseline and at 12 months (end of intervention)
|
Acceptability of Intimate Partner Violence Against Women Scale.
Martín-Fernández, Gracia, Marco, Vargas, Santirso and Lila (2018).
Total scale range: 0-40 (Higher values indicate worse outcome)
|
At baseline and at 12 months (end of intervention)
|
Change in benevolent sexism
Time Frame: At baseline and at 12 months (end of intervention)
|
Ambivalent Sexism Inventory.
Glick y Fiske, 1996.
Two sub-scales: Benevolent sexism (sub-scale range: 0-55) and Hostile sexism (sub-scale range: 0-55).
Higher values indicate worse outcome
|
At baseline and at 12 months (end of intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Marisol Lila, PhD, University of Valencia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2019
Primary Completion (Estimated)
November 30, 2025
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
February 5, 2019
First Submitted That Met QC Criteria
March 19, 2019
First Posted (Actual)
March 21, 2019
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H1537520365110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Abuse
-
Lund UniversityCompletedIntravenous Drug Abuse, S Aureus Colonization
-
Duke UniversityCompletedHealth Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and DependencyUnited States
-
Stuart WillickSports Medicine Research and Testing Laboratory; Partnership for Clean CompetitionCompletedSports Drug Abuse | Abuse of Steroids or HormonesUnited States
-
Eli Lilly and CompanyCompletedPrescription Drug Abuse (Not Dependent) | Recreational Drug UseUnited States
-
Boston UniversityNational Institute on Drug Abuse (NIDA)WithdrawnIntravenous Drug Abuse
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)United States
-
INSYS Therapeutics IncCompletedDrug Abuse, MedicationCanada
-
National Institute on Drug Abuse (NIDA)Completed
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)Completed
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
Clinical Trials on SBIP+ ADAPs-IMP
-
University of BolognaUnknown
-
Postgraduate Institute of Dental Sciences RohtakUnknownPeriodontal Bone LossIndia
-
Air Force Military Medical University, ChinaCompleted
-
AvenCell Europe GmbHPHARMALOG Institut für klinische Forschung GmbHRecruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)Germany
-
University of YamanashiHuman Genome Center, Institute of Medical Science, University of TokyoUnknown
-
Centre René GauducheauCompletedSmall Cell Lung Cancer | CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)France
-
Nantes University HospitalTerminatedMetastatic Colorectal CancerFrance
-
University of NottinghamTerminated
-
University of EdinburghNHS LothianCompleted